Information Provided By: 
Fly News Breaks for August 22, 2017
TXMD
Aug 22, 2017 | 07:19 EDT
Deutsche Bank analyst Esther Rajavelu said her survey of 525 potential patients for TherapeuticsMD's TX-004 bodes well for the drug's use if it is approved. While she is not changing her estimates, she said the survey could point to the potential for a steeper launch curve for TX-004. Rajavelu keeps a Buy rating and $10 price target on TherapeuticsMD shares.
News For TXMD From the Last 2 Days
There are no results for your query TXMD
